Trichostatin A alters cytoskeleton and energy metabolism of pancreatic adenocarcinoma cells: An in depth proteomic study

Journal of Cellular Biochemistry

Volumn 119, Issue 3, 2018, Pages 2696-2707

  Dalla Pozza, Elisa ^a   Manfredi, Marcello ^b   Brandi, Jessica ^a   Buzzi, Arianna ^b   Conte, Eleonora ^b   Pacchiana, Raffaella ^a   Cecconi, Daniela ^a   Marengo, Emilio ^b   Donadelli, Massimo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

2 deoxy d glucose; cytoskeleton; metabolism; pancreatic cancer; shotgun proteomics; trichostatin A

Indexed keywords

BETA ACTIN; DEOXYGLUCOSE; ELONGATION FACTOR 1; KERATIN TYPE I; KERATIN TYPE II; PROTEIN S 100; RIBOSOME PROTEIN; TRICHOSTATIN A; HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL GROWTH; CONTROLLED STUDY; CYTOSKELETON; DRUG POTENTIATION; ENERGY METABOLISM; HUMAN; HUMAN CELL; KERATINIZATION; MALE; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL CARCINOMA CELL LINE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEOMICS; UPREGULATION; DRUG EFFECT; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CYTOSKELETON; ENERGY METABOLISM; HUMANS; HYDROXAMIC ACIDS; PANCREATIC NEOPLASMS; PROTEOMICS;

EID: 85034662600     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.26436     Document Type: Article

References (31)

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74:2913–2921.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004; 363:1049–1057.
3. Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther. 2010; 3:111–127.
4. Lee HS, Park SB, Kim SA, et al. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Sci Rep. 2017; 7:41615.
5. Donadelli M, Costanzo C, Faggioli L, et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog. 2003; 38:59–69.
6. Moore PS, Barbi S, Donadelli M, et al. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta. 2004; 1693:167–176.
7. Cecconi D, Donadelli M, Scarpa A, et al. Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. J Proteome Res. 2005; 4:1909–1916.
8. Donadelli M, Costanzo C, Beghelli S, et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta. 2007; 1773:1095–1106.
9. Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther. 2014; 143:323–336.
10. Cecconi D, Palmieri M, Donadelli M. Proteomics in pancreatic cancer research. Proteomics. 2011; 11:816–828.
11. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5:769–784.
12. Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in combination with a second cytotoxic agent in the first-line treatment of locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Target Oncol. 2017; 12:309–321.
13. Cecconi D, Scarpa A, Donadelli M, et al. Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. Electrophoresis. 2003; 24:1871–1878.
14. Jungblut PR, Holzhutter HG, Apweiler R, Schluter H. The speciation of the proteome. Chem Cent J. 2008; 2:16.
15. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27–55.
16. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012; 11:O111016717.
17. Manfredi M, Martinotti S, Gosetti F, Ranzato E, Marengo E. The secretome signature of malignant mesothelioma cell lines. J Proteomics. 2016; 145:3–10.
18. Martinotti S, Patrone M, Manfredi M, et al. HMGB1 osteo-modulatory action on osteosarcoma saOS-2 cell line: an integrated study from biochemical and -omics approaches. J Cell Biochem. 2016; 117:2559–2569.
19. Tsou CC, Avtonomov D, Larsen B, et al. DIA-Umpire: comprehensive computational framework for data-independent acquisition proteomics. Nat Methods. 2015; 12:258–264.
20. Tsou CC, Tsai CF, Teo GC, Chen YJ, Nesvizhskii AI. Untargeted, spectral library-free analysis of data-independent acquisition proteomics data generated using Orbitrap mass spectrometers. Proteomics. 2016; 16:2257–2271.
21. Mi H, Huang X, Muruganujan A, et al. PANTHER version 11: expanded annotation data from gene ontology and reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 2017; 45:D183–D189.
22. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015; 43:D447–D452.
23. Eckhart L, Lippens S, Tschachler E, Declercq W. Cell death by cornification. Biochim Biophys Acta. 2013; 1833:3471–3480.
24. Fortier AM, Asselin E, Cadrin M. Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation. J Biol Chem. 2013; 288:11555–11571.
25. Schutte B, Henfling M, Kolgen W, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res. 2004; 297:11–26.
26. Dey P, Togra J, Mitra S. Intermediate filament: structure, function, and applications in cytology. Diagn Cytopathol. 2014; 42:628–635.
27. Charras GT. A short history of blebbing. J Microsc. 2008; 231:466–478.
28. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010; 10:254–266.
29. Zhou X, Liao WJ, Liao JM, Liao P, Lu H. Ribosomal proteins: functions beyond the ribosome. J Mol Cell Biol. 2015; 7:92–104.
30. Yin H, Liu T, Zhang Y, Yang B. Caveolin proteins: a molecular insight into disease. Front Med. 2016; 10:397–404.
31. Chatterjee M, Ben-Josef E, Thomas DG, et al. Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep. 2015; 5:10867.